Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited)

v3.10.0.1
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Statement Line Items [Line Items]        
Revenue
Expenses:        
Research and development (note 9) 3,591 1,390 14,549 4,213
General and administrative (note 9) 2,020 1,319 8,233 4,302
Operating Expenses 5,611 2,709 22,782 8,515
Finance expense (note 9) 20
Finance income (note 9) (89) (69) (198) (142)
Net finance income (89) (69) (178) (142)
Net loss and comprehensive loss for the period $ (5,522) $ (2,640) $ (22,604) $ (8,373)
Basic and diluted loss per common share (in dollars per share) $ (0.16) $ (0.11) $ (0.71) $ (0.40)
Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per common share (000s) note 6(b) (in shares) 34,587 24,061 32,039 20,954